Magnetar Financial LLC Sells 17,005 Shares of West Pharmaceutical Services, Inc. (NYSE:WST)

Magnetar Financial LLC lessened its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 81.2% during the 1st quarter, Holdings Channel reports. The firm owned 3,926 shares of the medical instruments supplier’s stock after selling 17,005 shares during the period. Magnetar Financial LLC’s holdings in West Pharmaceutical Services were worth $1,554,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Evoke Wealth LLC bought a new stake in West Pharmaceutical Services during the 4th quarter valued at approximately $7,770,000. Sumitomo Mitsui Trust Holdings Inc. raised its stake in West Pharmaceutical Services by 1.5% during the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 191,469 shares of the medical instruments supplier’s stock valued at $75,766,000 after purchasing an additional 2,759 shares during the period. International Assets Investment Management LLC raised its stake in West Pharmaceutical Services by 13,230.0% during the 4th quarter. International Assets Investment Management LLC now owns 18,662 shares of the medical instruments supplier’s stock valued at $6,571,000 after purchasing an additional 18,522 shares during the period. Vanguard Group Inc. raised its stake in West Pharmaceutical Services by 1.2% during the 4th quarter. Vanguard Group Inc. now owns 9,002,632 shares of the medical instruments supplier’s stock valued at $3,170,007,000 after purchasing an additional 104,740 shares during the period. Finally, Mizuho Markets Americas LLC raised its stake in West Pharmaceutical Services by 142.3% during the 1st quarter. Mizuho Markets Americas LLC now owns 29,628 shares of the medical instruments supplier’s stock valued at $11,724,000 after purchasing an additional 17,399 shares during the period. Institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services Price Performance

NYSE WST traded up $7.60 during trading on Friday, hitting $284.76. 1,190,418 shares of the stock traded hands, compared to its average volume of 675,234. The company has a market capitalization of $20.74 billion, a P/E ratio of 37.57, a price-to-earnings-growth ratio of 6.03 and a beta of 1.00. The firm has a 50-day simple moving average of $324.09 and a 200-day simple moving average of $355.79. The company has a quick ratio of 1.95, a current ratio of 2.61 and a debt-to-equity ratio of 0.03. West Pharmaceutical Services, Inc. has a 12-month low of $265.00 and a 12-month high of $415.73.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 earnings per share for the quarter, missing the consensus estimate of $1.74 by ($0.22). The firm had revenue of $702.10 million for the quarter, compared to analysts’ expectations of $729.36 million. West Pharmaceutical Services had a net margin of 18.25% and a return on equity of 18.78%. The business’s quarterly revenue was down 6.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.11 EPS. As a group, analysts predict that West Pharmaceutical Services, Inc. will post 6.4 EPS for the current year.

Insider Activity at West Pharmaceutical Services

In related news, SVP Silji Abraham sold 1,800 shares of the business’s stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $330.78, for a total transaction of $595,404.00. Following the completion of the transaction, the senior vice president now owns 2,860 shares in the company, valued at approximately $946,030.80. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, CEO Eric Mark Green sold 66,000 shares of the business’s stock in a transaction on Tuesday, May 7th. The stock was sold at an average price of $366.65, for a total transaction of $24,198,900.00. Following the completion of the transaction, the chief executive officer now owns 152,908 shares in the company, valued at approximately $56,063,718.20. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Silji Abraham sold 1,800 shares of the business’s stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $330.78, for a total value of $595,404.00. Following the transaction, the senior vice president now owns 2,860 shares of the company’s stock, valued at approximately $946,030.80. The disclosure for this sale can be found here. 0.53% of the stock is owned by company insiders.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.